

Thymosin Beta-4 (17-23)

Category: Healing & Recovery

Description

The 17-23 fragment of thymosin beta-4 (LKKTETQ) is the minimal active sequence responsible for actin-binding and tissue remodeling activity of the full TB-500 molecule.

Protocol & Dosage

Recommended dosage: 500 mcg 1 mg, 2 3x weekly

Biological half-life: 3 5 hours

Administration: Subcutaneous injection (typical)

Key Benefits & Mechanisms

- ∨267 Promotes actin polymerization

- ∨267 Connective tissue repair

- ∨267 Anti-inflammatory

- ∨267 Faster recovery

- ∨267 Wound healing

Side Effects & Safety Profile

- ∨267 Mild fatigue

- ∨267 Headache

- ∨267 Injection site redness

Important Disclaimer

This document is provided for educational and research purposes only.

Peptides discussed herein are not approved for clinical use without physician oversight.

Never attempt self-administration without professional medical supervision.

Black market peptides can be contaminated, mislabeled, or dangerous.